Clinical Trials Logo
  1. Home
  2. Crohn's Disease
  3. NCT01086553

9 mg Budesonide Once Daily (OD) Versus 3 mg Budesonide Three Times Daily (TID) in Active Crohn's Disease

Crohn´s Disease Clinical Trial

Official title:
Double-blind, Double-dummy, Randomised, Comparative, Multi-centre Phase III Study on the Efficacy and Tolerability of an 8-week Oral Treatment With 9 mg Budesonide Once Daily vs. 3 mg Budesonide Three-times Daily in Patients With Active Crohn's Disease

Clinical Trial Summary

This study aims to evaluate the efficacy of 9 mg budesonide once daily (OD) versus 3 mg budesonide three-times daily (TID) for the induction of remission in Crohn's disease.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01086553
Study type Interventional
Source Dr. Falk Pharma GmbH
Contact
Status Completed
Phase Phase 3
Start date November 2009
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Completed NCT01860651 - Web-based Monitoring in Children and Adolescents With Inflammatory Bowel Disease N/A
Completed NCT01102855 - Endomicroscopy and Crohn´s Disease N/A
Completed NCT01279577 - Trichuris Suis Ova (TSO) Suspension Versus Placebo in Active Crohn's Disease Phase 2
Completed NCT02763293 - Osteopathy Non-manipulative in Patients With Crohn's Disease. N/A
Completed NCT01289366 - Endocytoscopy for in Vivo Determination of Mucosal Inflammatory Cells and Intestinal Disease Activity in Inflammatory Bowel Disease (IBD) N/A
Recruiting NCT06006039 - The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.
Recruiting NCT04022083 - Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Completed NCT03890445 - Real-world Study of Anti-TNFa Treatment Regimes of Hyrimoz or Zessly in Patients With Crohn´s Disease
Completed NCT01564823 - Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease Phase 3
Completed NCT01768858 - Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Adherence Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice
Completed NCT01417715 - Endomicroscopy for Assessment of Mucosal Healing
Completed NCT01417702 - Endoscopy for Assessment of Mucosal Healing in IBD
Terminated NCT00862121 - A Study With Pentasa in Patients With Active Crohn's Disease Phase 3